Gilead Sciences
Biotech Investor · 2 portfolio companies
Portfolio
2
Combined Value
$2.0B
Focus Areas
3
Top Stage
Phase 1
Investment Focus
Portfolio Companies
| Company | Valuation |
|---|---|
| Nurix Therapeutics | $1.5B |
| Kyverna Therapeutics | $473.3M |
Biotech Investor · 2 portfolio companies
| Company | Valuation |
|---|---|
| Nurix Therapeutics | $1.5B |
| Kyverna Therapeutics | $473.3M |